Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 35

1.

Targeting of CDK9 with indirubin 3'-monoxime safely and durably reduces HIV viremia in chronically infected humanized mice.

Medina-Moreno S, Dowling TC, Zapata JC, Le NM, Sausville E, Bryant J, Redfield RR, Heredia A.

PLoS One. 2017 Aug 17;12(8):e0183425. doi: 10.1371/journal.pone.0183425. eCollection 2017.

2.

The therapeutic landscape of HIV-1 via genome editing.

Kwarteng A, Ahuno ST, Kwakye-Nuako G.

AIDS Res Ther. 2017 Jul 14;14(1):32. doi: 10.1186/s12981-017-0157-8. Review.

3.

Positive cyclin T expression as a favorable prognostic factor in treating gastric gastrointestinal stromal tumors.

Lin LF, Jin JS, Chen JC, Huang CC, Sheu JH, Chen W, Tsao TY, Hsu CW.

Mol Clin Oncol. 2016 Jun;4(6):971-975. Epub 2016 Mar 30.

4.

Increased cyclin T1 expression as a favorable prognostic factor in treating gastric adenocarcinoma.

Jin JS, Lin LF, Chen JC, Huang CC, Sheu JH, Chen W, Tsao TY, Hsu CW.

Oncol Lett. 2015 Dec;10(6):3712-3718. Epub 2015 Sep 25.

5.

The emerging role of long non-coding RNAs in HIV infection.

Lazar DC, Morris KV, Saayman SM.

Virus Res. 2016 Jan 2;212:114-26. doi: 10.1016/j.virusres.2015.07.023. Epub 2015 Jul 26. Review.

6.

RNA interference approaches for treatment of HIV-1 infection.

Bobbin ML, Burnett JC, Rossi JJ.

Genome Med. 2015 May 28;7(1):50. doi: 10.1186/s13073-015-0174-y. eCollection 2015.

7.

High-throughput RNA interference screens integrative analysis: Towards a comprehensive understanding of the virus-host interplay.

Amberkar S, Kiani NA, Bartenschlager R, Alvisi G, Kaderali L.

World J Virol. 2013 May 12;2(2):18-31. doi: 10.5501/wjv.v2.i2.18. Review.

8.

Herpes simplex virus 1 ICP22 inhibits the transcription of viral gene promoters by binding to and blocking the recruitment of P-TEFb.

Guo L, Wu WJ, Liu LD, Wang LC, Zhang Y, Wu LQ, Guan Y, Li QH.

PLoS One. 2012;7(9):e45749. doi: 10.1371/journal.pone.0045749. Epub 2012 Sep 24.

9.

Regulation of cyclin T1 and HIV-1 Replication by microRNAs in resting CD4+ T lymphocytes.

Chiang K, Sung TL, Rice AP.

J Virol. 2012 Mar;86(6):3244-52. doi: 10.1128/JVI.05065-11. Epub 2011 Dec 28.

10.

Antiviral RNAi: translating science towards therapeutic success.

Shah PS, Schaffer DV.

Pharm Res. 2011 Dec;28(12):2966-82. doi: 10.1007/s11095-011-0549-8. Epub 2011 Aug 9. Review.

11.

Limited redundancy in genes regulated by Cyclin T2 and Cyclin T1.

Ramakrishnan R, Yu W, Rice AP.

BMC Res Notes. 2011 Jul 26;4:260. doi: 10.1186/1756-0500-4-260.

12.

HIV-1 replication and latency are regulated by translational control of cyclin T1.

Hoque M, Shamanna RA, Guan D, Pe'ery T, Mathews MB.

J Mol Biol. 2011 Jul 29;410(5):917-32. doi: 10.1016/j.jmb.2011.03.060.

13.

Controlling cellular P-TEFb activity by the HIV-1 transcriptional transactivator Tat.

Muniz L, Egloff S, Ughy B, Jády BE, Kiss T.

PLoS Pathog. 2010 Oct 14;6(10):e1001152. doi: 10.1371/journal.ppat.1001152.

14.

Cyclin T1/CDK9 interacts with influenza A virus polymerase and facilitates its association with cellular RNA polymerase II.

Zhang J, Li G, Ye X.

J Virol. 2010 Dec;84(24):12619-27. doi: 10.1128/JVI.01696-10. Epub 2010 Oct 13.

15.

P-TEFb kinase complex phosphorylates histone H1 to regulate expression of cellular and HIV-1 genes.

O'Brien SK, Cao H, Nathans R, Ali A, Rana TM.

J Biol Chem. 2010 Sep 24;285(39):29713-20. doi: 10.1074/jbc.M110.125997. Epub 2010 Jun 15.

16.

RNA interference-based therapeutics for human immunodeficiency virus HIV-1 treatment: synthetic siRNA or vector-based shRNA?

Subramanya S, Kim SS, Manjunath N, Shankar P.

Expert Opin Biol Ther. 2010 Feb;10(2):201-13. doi: 10.1517/14712590903448158. Review.

17.

Selective control of gene expression by CDK9 in human cells.

Garriga J, Xie H, Obradovic Z, Graña X.

J Cell Physiol. 2010 Jan;222(1):200-8. doi: 10.1002/jcp.21938.

18.

Novel HIV-1 therapeutics through targeting altered host cell pathways.

Coley W, Kehn-Hall K, Van Duyne R, Kashanchi F.

Expert Opin Biol Ther. 2009 Nov;9(11):1369-82. doi: 10.1517/14712590903257781. Review.

19.

P-TEFb- the final frontier.

Kohoutek J.

Cell Div. 2009 Sep 2;4:19. doi: 10.1186/1747-1028-4-19.

20.

Identification of flavopiridol analogues that selectively inhibit positive transcription elongation factor (P-TEFb) and block HIV-1 replication.

Ali A, Ghosh A, Nathans RS, Sharova N, O'Brien S, Cao H, Stevenson M, Rana TM.

Chembiochem. 2009 Aug 17;10(12):2072-80. doi: 10.1002/cbic.200900303.

Supplemental Content

Support Center